Disease landscape
Prostate Cancer
The GAP analysis revealed moderate limitations in access to ovarian cancer treatment and diagnosis in the Visegrad Group (V4) countries. There is noticeable variation in results between countries: the difference between the highest and lowest scores is 24 points. The variance in GAP scores is driven mainly by differences in the diagnostic quality and the limited access to the selected novel drugs.
Cross-Country
General GAP for Prostate Cancer
Compliance with guidelines
Of the 9 drugs recommended by the clinical practice guidelines, about 70% are available in the V4 group. The spread of results for this KPI is large (33 percentage points), indicating a wide variation in access to the latest authorized drugs in these countries.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Selected novel drugs
Drug access
Number of patients treated (2023)
Drug access
Population treated (%) - selected drugs*
*percentage of the population potentially eligible for treatment with selected drugs: Erleada, Nubeqa, Xtandi, Zytiga.
Main issues
- The average time to reimbursement for prostate cancer drugs in the V4 countries is 3.1 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 2.2 years.
- The proportion of patients in the target population treated with the selected novel drugs in V4 countries varies substantially with only 35-37% of potentially eligible patients treated with these options in Czechia and Hungary and over 60% in Poland and over 90% in Slovakia.
- All V4 states have a significant population burden in prostate cancer. The burden measured by DALYs (disability adjusted life-years) in these countries is however lower than the EU average.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).